What is it about?
We performed a single-centre retrospective cohort study of 65 consecutive patients (pts) with unresectable or metastatic CS treated with first-line palliative CHT. Overall survival (OS) and progression-free Survival (PFS) were estimated using the Kaplan-Meier method, and potential prognostic factors, including systemic inflammation indexes [neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII)], were assessed using the log-rank test and exploratory Cox models.
Featured Image
Photo by Cara Shelton on Unsplash
Why is it important?
Advanced chondrosarcoma (CS) is characterised by limited chemosensitivity with surgery remaining the mainstay of treatment and resultant poor survival. Real-world data on palliative chemotherapy (CHT) and prognostic biomarkers are scarce.
Perspectives
Systemic inflammation markers such as the NLR emerged as a promising prognostic tool with the potential to refine risk stratification in advanced CS. The frequent use of subsequent chemotherapy lines and local therapies (metastasectomy, stereotactic radiotherapy) highlights the need for individualized, multimodal management od CS patients.
Piotr Remiszewski
Maria Sklodowska- Curie National Research Institute of Oncology
Read the Original
This page is a summary of: 141P Inflammatory prognostic factors and long-term outcomes of chondrosarcoma patients treated with palliative chemotherapy, ESMO Rare Cancers, March 2026, Elsevier,
DOI: 10.1016/j.esmorc.2026.100347.
You can read the full text:
Resources
Contributors
The following have contributed to this page
